ClinicalTrials.gg
CompletedNCT01886339SNIF REF VUpdated Mar 20, 2017

SNIF (Sniff Nasal Inspiratory Force) Reference Values Of Mediterranean Population

An observational study in Healthy People Programs, sponsored by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau. Completed at 1 site in Spain. Open to participants aged 20 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-03-20.

Sponsored by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Observational

Study type
Observational
Model
Ecologic or community
Time perspective
Prospective
Enrollment
439
Ages
20 Years to 70 Years
Sex
All
01

Study summary

SNIF test has been described as a method to explore the diaphragmatic function. But there are no defined the reference values of this test in healthy population. The investigators' hypothesis is that there is a variation on SNIF values in Mediterranean population depending on gender, age and anthropometric variables such as height and weight.

The investigators will analyze 1000 SNIF test of healthy people. The investigators will divide in 5 groups of age (20-30, 30-40, 40-50, 50-60, 60-70) and in each group the investigators will study 100 men and 100 women.

All the subjects will perform a forced spirometry, maximal inspiratory pressure (MIP) and SNIF. If spirometry and MIP are correct the investigators will consider that person has a correct diaphragmatic function and strength. Then the investigators will measure the SNIF test. With all of these SNIF values the investigators will try to achieve the reference values of this test in the different groups of age in Mediterranean population. And the investigators will compare SNIF with MIP.

Cross multicentric study. Hospitals involved: Hospital de Bellvitge, Hospital del Mar, Hospital Parc Taulí, Hospital de la Santa Creu i Sant Pau (coordinator center) and Hospital de la Vall d'Hebrón.

02

Conditions studied

  • Healthy People Programs
03

In context

Lead sponsor

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau is the lead sponsor of 342 studies on the registry; 64 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Community sample

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy people with spirometry and MIP values in the reference range
  • Age between 20 and 70 years old
  • Caucasian race

Exclusion criteria

Exclusion Criteria:

  • Rhinitis
  • Nasal obstruction
  • Frequent episodes of epistaxis
  • Ongoing cold
05

Study design

Observational model
Ecologic or community
Time perspective
Prospective
Enrollment
439 participants (actual)
Patient registry
No

Groups and cohorts

  • Healthy population

    Other: SNIF test (Sniff Nasal Inspiratory Force)

Interventions

  • OtherSNIF test (Sniff Nasal Inspiratory Force)
06

What researchers measure

Primary outcomes

  1. SNIF test

    Main objectives: * To define the SNIF reference values in a healthy Mediterranean population. * Analyze the influence of different variables such as gender, age, height and weight on this measure.

    Time frame: Basal

07

Study locations

1 site
  • Hospital de la Santa Creu i Sant Pau
    Barcelona, Barcelona 08025, Spain
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2010, a primary completion of Jan 2016 and a completion of Jun 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2013
First posted
Jun 25, 2013
Start
Jun 2010
Primary completionActual
Jan 2016
CompletionActual
Jun 2016
Last update
Mar 20, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01886339
Responsible party
Sponsor
First posted
Jun 25, 2013
Start date
Jun 2010
Primary completion
Jan 2016
Completion
Jun 2016
Last update
Mar 20, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion